Concepedia

Badry Bursulaya

BB

Statistics

Publications

61

Citations

7.9K

H-Index

42

Active since

1995

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Scripps Research Institute

Carnegie Mellon University

Novartis (United States)

Novartis (Switzerland)

Badry Bursulaya is an author at Genomics Institute of the Novartis Research Foundation specializing in drug discovery, pharmacology, and medicinal chemistry.

Publications per year

1995–2022

61

Publications

61

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

Yong Jia, Cai‐Hong Yun, Eunyoung Park et al. · Nature · 2016 · 879 citations · Full text

, , +11

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang, Francisco Adrián, Wolfgang Jahnke et al. · Nature · 2010 · 599 citations

, , +14

Targeting Plasmodium PI(4)K to eliminate malaria

Case W. McNamara, Chek Shik Lim, Siau Hoi Lim et al. · Nature · 2013 · 426 citations · Full text

, , +12

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

Shilpi Khare, A. S. Nagle, Agnes Biggart et al. · Nature · 2016 · 420 citations · Full text

, , +16

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Thomas H. Marsilje, Wei Pei, Bei Chen et al. · Journal of Medicinal Chemistry · 2013 · 412 citations · Full text

, , +16

1–5 of 61